Discover J&J
Medicines & therapies
Medical devices & technology
Discover J&J
Medicines & therapies
Medical devices & technology
Careers
Media
Contact
locationPlaceholder
Choose your country or region
Global
Global
English
North America
North America (Regional)
English
Canada
English
Français
United States
English
Asia Pacific
Asia Pacific (Regional)
English
Australia
English
China
中文
Hong Kong
English
中文
Japan
日本
Korea
한국어
New Zealand
English
Europe, Middle East & Africa (EMEA)
EMEA (Regional)
English
Middle East - Africa
الشرق الأوسط و أفريقيا (عربي)
Austria
Deutsch
Belgium
English
Français
Nederlands
Bulgaria
БЪЛГАРСКИ
Croatia
Hrvatski
Czech Republic
čeština
Denmark
Dansk
Estonia
English
Finland
Suomi
France
Français
Germany
Deutsch
Greece
ΕΛΛΗΝΙΚΑ
Hungary
Magyar
Ireland
English
Israel
עברית
Italy
Italiano
Latvia
English
Lithuania
English
Netherlands
Nederlands
Norway
Norsk
Poland
Polski
Portugal
Português
Romania
Română
Russia
Pусский
Serbia
Srpski
Slovakia
Slovenčina
Slovenia
Slovenščina
South Africa
English
Spain
Español
Switzerland
Français
Deutsch
Sweden
Svensk
Turkey
Türkçe
United Kingdom
English
Latin America
Latin America (Regional)
Español
Argentina
Español
Bolivia
Español
Brazil
Português
Central America and the Caribbean
Español
Chile
Español
Colombia
Español
Ecuador
Español
Mexico
Español
Paraguay
Español
Peru
Español
Uruguay
Español
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Innovative Medicine
healthcare areas
Menu
Healthcare areas
Oncology
Immunology
Neuroscience
Cardiopulmonary
Products
Clinical trials
Pipeline
Patient resources
Careers
Media
Contact
Show Search
Search Query
Clear
Submit Search
Dictate search request
Listening...
Search Results
No Results
See all results
Sorry, I don't understand. Please try again
Search Results
Search Query
Submit Search
Listening...
Dates
All (1125)
Last 7 days (2)
2024 (101)
2023 (76)
2022 (58)
2021 (67)
2020 (42)
2019 (68)
2018 (77)
2017 (80)
2016 (64)
Types
All (1125)
Article (56)
Page (7)
Press Release (1062)
There are 1,125 results that match your search.
Filters
Dates
All (1125)
Last 7 days (2)
2024 (101)
2023 (76)
2022 (58)
2021 (67)
2020 (42)
2019 (68)
2018 (77)
2017 (80)
2016 (64)
Types
All (1125)
Article (56)
Page (7)
Press Release (1062)
Relevance
Relevance
Newest
Oldest
Innovative Medicine
October 11, 2017
Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
First Agent Submitted to Address a Critical Need in Earlier Stage Castration-Resistant Prostate Cancer at High-Risk for Metastasis
Read more
Innovative Medicine
October 6, 2017
Janssen Announces Pivotal Phase 3 Study Results for Investigational Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection in Adults Switching from Boosted Protease Inhibitors Plus Emtricitabine and Tenofovir Disoproxil Fumarate Regimens
EMERALD 48-week safety and efficacy results published in The Lancet HIV and to be presented at IDWeek
Read more
Innovative Medicine
October 5, 2017
NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms
Read more
Innovative Medicine
October 2, 2017
Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
Filing includes data on the combined risk reduction of cardiovascular death, myocardial infarction and stroke in patients with type 2 diabetes
Read more
Global health equity
September 29, 2017
Johnson & Johnson Advances Investigational Ebola Prime-boost Vaccine Regimen with New Partnership
Read more
Innovative Medicine
September 22, 2017
JANSSEN RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FDA FOR SIRUKUMAB BIOLOGICS LICENSE APPLICATION
Read more
Innovative Medicine
September 18, 2017
NEW TWO-YEAR TREMFYA™ (GUSELKUMAB) DATA SHOW PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS ACHIEVED CONSISTENT RATES OF SKIN CLEARANCE
More than 80 percent of patients receiving TREMFYA™, including patients transitioned from Humira® to the anti-interleukin (IL)-23 monoclonal antibody, demonstrated PASI 90 and IGA 0/1 scores at week 100
Read more
Innovative Medicine
September 15, 2017
JANSSEN RECEIVES CHMP POSITIVE OPINION FOR GUSELKUMAB RECOMMENDING APPROVAL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN THE EUROPEAN UNION
Pending approval, guselkumab will be the first biologic that selectively blocks interleukin (IL)-23
Read more
Innovative Medicine
September 15, 2017
Johnson & Johnson Announces Collaboration with U.S. Department of Health and Human Services to Fight Influenza
Janssen and Biomedical Advanced Research and Development Authority (BARDA) join forces to accelerate new therapies and vaccines to protect communities against the threat of a pandemic
Read more
Innovative Medicine
September 14, 2017
Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Filing Supported by Data from Pivotal LATITUDE Trial Evaluating ZYTIGA® in Combination with Prednisone and Androgen Deprivation Therapy (ADT)
Read more
70 of 113
